Concurrent Interdigitating Dendritic Cell Sarcoma and T-Lymphoblastic Leukemia/Lymphoma: A Case Report and Review of Literature
Article Sidebar
Main Article Content
Abstract
Interdigitating dendritic cell sarcoma (IDCS) is a rare tumor that arises from classical dendritic cells within the bone marrow. Typically, it is observed subsequent to the development of low-grade B-cell lymphoma. However, there has been only one documented case following T-acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL). The presence of these synchronous tumors with a clonal relationship, indicating a potential transdifferentiation of the tumor. We report a case of concurrent IDCS and T-ALL/LBL. A middle-aged male presented with painful cervical node enlargement. Biopsy revealed parafollicular proliferation of pleomorphic epithelioid cells expressing S100. Immunohistochemistry excluded alternative dendritic cell tumors and melanoma, confirming IDCS diagnosis. Four months post-treatment, generalized lymphadenopathy emerged, revealing small immature T cells clustering amidst IDCS cells in both lymph nodes and bone marrow. Genetic analysis identified NRAS mutation in IDCS but not in T-ALL/LBL, whereas TCR gene rearrangement was detected in T-ALL/LBL but absent in IDCS. Unfortunately, we lack conclusive evidence regarding the clonal relationship or transdifferentiation between these two tumors. They could be unrelated and incidentally develop at the same time.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Weiss LM, Chan JKC. Interdigitating dendritic cell sarcoma. Histiocytic and dendritic cell neoplasms, WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th Edition, Volume 2. 2017;2:475-6.
Saygin C, Uzunaslan D, Ozguroglu M, et al. Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series. Crit Rev Oncol Hematol. 2013;88(2):253-71. doi: 10.1016/j.critrevonc.2013.05.006.
Johansson B, Ingvarsson S, Björck P, et al. Human interdigitating dendritic cells induce isotype switching and IL-13-dependent IgM production in CD40-activated naive B cells. J Immunol. 2000 Feb 15;164(4):1847-54. doi: 10.4049/jimmunol.164.4.1847.
Fraser CR, Wang W, Gomez M, et al. Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone. Am J Clin Pathol. 2009;132(6):928-39. doi: 10.1309/AJCPWQ0I0DGXBMHO.
Feldman AL, Berthold F, Arceci RJ, et al. Clonal relationship between precursor T-lymphoblastic leukemia/lymphoma and langerhans-cell histiocytosis. Lancet Oncol. 2005;6(6):435-7. doi: 10.1016/S1470-2045(05)70211-4.
Feldman AL, Minniti C, Santi M, et al. Histiocytic sarcoma after acute lymphoblastic leukemia: a common clonal origin. Lancet Oncol. 2004;5(4):248-50. doi: 10.1016/S1470- 2045(04)01428-7.
Horschowski N, Guitard AM, Arnoux I, et al. Interdigitating cell sarcoma: occurrence during incomplete remission of a lymphoblastic lymphoma. Pathol Biol (Paris). 1993;41(3):255-9.
Luis MJS, Samir D, Diego CR, et al. “Interdigitating Dendritic Cell Sarcoma.” Atlas of Genetics and Cytogenetics in Oncology and Haematology, December 2018.
Xue T, Jiang XN, Wang WG, et al. Interdigitating dendritic cell sarcoma: clinicopathologic study of 8 cases with review of the literature. Ann Diagn Pathol. 2018;34:155-160. doi: 10.1016/j.anndiagpath.2018.03.008.
Li X, Calaminici M, Wang H ,et al. Interdigitating Dendritic Cell Sarcoma. WHO Classification of Tumours Editorial Board. Haematolymphoid Tumours, International Agency for Research on Cancer, 2022. Web. 14 May 2023. (WHO classification of tumours series, 5th ed.; vol.11). Available from: https://tumourclassification.iarc.who.int/chaptercontent/63/104.
Rodig SJ, Payne EG, Degar BA, et al. “Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1. Am J Hematol. 2008;83(2):116-21. doi: 10.1002/ajh.21044.
Newman DorlandW. Dorland’s Illustrated Medical Dictionary. 2018.
Sin CF, Man PM. Early T-cell precursor acute lymphoblastic leukemia. Front Oncol. 2021;11:750789. doi: 10.3389/ fonc.2021.750789. eCollection 2021.
Xiao W, Chen W, Tembhare P, et al. “Mixed-Phenotype Acute Leukaemia, T/Myeloid.” WHO Classification of Tumours Editorial Board. Haematolymphoid Tumours, International Agency for Research on Cancer, 2022. Web. 19 March 2024. (WHO classification of tumours series, 5th ed.; vol.11). Available from: https://tumourclassification.iarc.who.int/chaptercontent/63/81.
Czader M, Molina TJ, Choi JK, et al. Early T-precursor lymphoblastic leukaemia/lymphoma. WHO Classification of Tumours Editorial Board. Haematolymphoid Tumours, International Agency for Research on Cancer, 2022. Web. 12 November 2024. (WHO classification of tumours series, 5th ed.; vol.11). Available from: https://tumourclassification.iarc. who.int/chaptercontent/63/205
Wang Y, Xiang Y, Xin VW, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020;13(1):107. doi: 10.1186/s13045-020-00939-6.
Kanagal-Shamanna R, Germing U, Bejar R, et al. Myeloid neoplasm post cytotoxic therapy. WHO Classification of Tumours Editorial Board. Haematolymphoid Tumours, International Agency for Research on Cancer, 2022. Web. 28 January 2025. (WHO classification of tumours series, 5th ed.; vol.11). Available from: https://tumourclassification.iarc.who. int/chaptercontent/63/27
Saygin C, Kishtagari A, Cassaday RD, et al. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019;3(24):4228-4237. doi: 10.1182/bloodadvances.2019000925.